EYPT EyePoint Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EYPT

Price (delayed)

$19.74

Market cap

$983.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.82

Enterprise value

$707.15M

EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a ...

Highlights
EYPT's equity has surged by 176% year-on-year
EYPT's quick ratio has surged by 145% since the previous quarter and by 13% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://eyepointpharma.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of EYPT
Market
Shares outstanding
49.83M
Market cap
$983.66M
Enterprise value
$707.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.62
Price to sales (P/S)
16.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.37
Earnings
Revenue
$46.02M
EBIT
-$69.47M
EBITDA
-$69M
Free cash flow
-$1.61M
Per share
EPS
-$1.82
Free cash flow per share
-$0.04
Book value per share
$7.54
Revenue per share
$1.18
TBVPS
$9.13
Balance sheet
Total assets
$355.18M
Total liabilities
$88.86M
Debt
$4.91M
Equity
$266.32M
Working capital
$281.54M
Liquidity
Debt to equity
0.02
Current ratio
5.45
Quick ratio
5.25
Net debt/EBITDA
4.01
Margins
EBITDA margin
-149.9%
Gross margin
89.9%
Net margin
-153.8%
Operating margin
-163.1%
Efficiency
Return on assets
-33.5%
Return on equity
-61.5%
Return on invested capital
-1,558.5%
Return on capital employed
-23.8%
Return on sales
-151%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EYPT stock price

How has the EyePoint Pharmaceuticals stock price performed over time
Intraday
-1%
1 week
17.85%
1 month
-4.87%
1 year
149.87%
YTD
-14.58%
QTD
-4.5%

Financial performance

How have EyePoint Pharmaceuticals's revenue and profit performed over time
Revenue
$46.02M
Gross profit
$41.39M
Operating income
-$75.07M
Net income
-$70.8M
Gross margin
89.9%
Net margin
-153.8%
The net margin has increased by 38% year-on-year and by 35% since the previous quarter
The company's operating margin rose by 32% QoQ and by 32% YoY
The net income rose by 31% year-on-year and by 29% since the previous quarter
The operating income has grown by 27% from the previous quarter and by 25% YoY

Growth

What is EyePoint Pharmaceuticals's growth rate over time

Valuation

What is EyePoint Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.62
P/S
16.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.37
The EPS has grown by 34% YoY and by 32% from the previous quarter
EYPT's equity has surged by 176% year-on-year
The stock's price to book (P/B) is 56% less than its 5-year quarterly average of 6.0 and 27% less than its last 4 quarters average of 3.6
EYPT's P/S is 114% above its 5-year quarterly average of 7.8 and 74% above its last 4 quarters average of 9.6
The revenue has increased by 11% year-on-year and by 8% since the previous quarter

Efficiency

How efficient is EyePoint Pharmaceuticals business performance
EyePoint Pharmaceuticals's ROE has soared by 55% from the previous quarter and by 17% YoY
EYPT's return on assets is up by 44% since the previous quarter and by 28% year-on-year
The ROS has grown by 37% YoY and by 35% from the previous quarter

Dividends

What is EYPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EYPT.

Financial health

How did EyePoint Pharmaceuticals financials performed over time
EYPT's quick ratio has surged by 145% since the previous quarter and by 13% year-on-year
EyePoint Pharmaceuticals's current ratio has soared by 132% from the previous quarter and by 9% YoY
The debt is 98% smaller than the equity
EYPT's equity has surged by 176% year-on-year
EYPT's debt to equity has dropped by 96% year-on-year and by 78% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.